Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure (Q86290868)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure |
clinical trial |
Statements
Paclitaxel Plus Cetuximab for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer After First-line Checkpoint Inhibitor Failure: A Multicenter, Single Arm Study (English)
0 references
February 2020
0 references
December 2021
0 references
50
0 references
18 year
0 references